Mode
Text Size
Log in / Sign up

BIRC3::MALT1 fusion detected in 35% of cells in pulmonary MALT lymphoma caseCase Report Shows Pulmonary MALT Lymphoma Diagnosis in Lung Nodule

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that mild FDG uptake in lung opacities requires pathologic confirmation before diagnosing lymphoma dissemination.

This case report describes the clinical presentation and diagnostic workup of a 49-year-old man with a pulmonary nodule diagnosed as pulmonary MALT lymphoma. The patient underwent video-assisted thoracoscopic right lower-lobe superior segmentectomy and rituximab-based systemic therapy.

Diagnostic evaluations included histopathology, immunohistochemistry, and FISH analysis. Histopathology supported the diagnosis of pulmonary MALT lymphoma, while FISH analysis detected a BIRC3::MALT1 fusion in 35% of analyzed cells. Post-operative PET/CT findings showed mildly avid right upper-lobe ground-glass opacities (SUVmax 1.0) and circumferential thickening of the horizontal duodenum (SUVmax 4.0).

A gastroscopy of the duodenum revealed no mucosal abnormalities, though a biopsy was not obtained from the gastrointestinal site. The authors note that mild FDG uptake in long-standing pulmonary opacities or unbiopsied gastrointestinal findings should not be interpreted as lymphoma dissemination without pathologic confirmation. Due to the single case nature, these findings do not establish general clinical guidelines for interpreting PET/CT results in MALT lymphoma.

How this fits prior evidence

This case report provides a specific example of pulmonary MALT lymphoma involving a BIRC3::MALT1 fusion. It does not relate to previous coverage regarding rituximab's use in multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, or DLBCL treatment.

While the report mentions rituximab as part of the systemic therapy for this patient, it does not provide data comparable to the prior evidence regarding its noninferiority to ocrelizumab in suppressing T2-weighted MRI lesions.

Doctors reported on a case involving a 49-year-old man who presented with a pulmonary nodule. Testing confirmed he had pulmonary MALT lymphoma, which is a specific type of lymphoma that can occur in the lungs. The medical team used both surgery and systemic therapy to treat the condition.

A key finding in this report involved how imaging results are interpreted. After surgery, PET scans showed some activity in other areas, such as the duodenum. However, further tests like a gastroscopy showed no abnormalities in those areas. This highlights that certain findings on a scan may not always indicate the spread of disease without a physical tissue sample.

Because this report describes only one patient, it is not used to create general medical rules. It serves as an example for doctors to be cautious when reading scans. They must ensure they do not assume cancer has spread just because a scan shows activity in an area that was not biopsied.

What this means for you:
A single case highlights the need for tissue samples to confirm if abnormal scan findings represent spreading lymphoma.

Common questions

What was found in the patient's lung nodule?

The medical team confirmed that the patient had a condition called pulmonary MALT lymphoma. They used histopathology and immunohistochemistry to confirm this diagnosis. During testing, they also detected a BIRC3::MALT1 fusion in 35% of the cells analyzed.

What did the PET scans show after surgery?

After surgery, the PET scan showed some activity in different areas. Specifically, it showed ground-glass opacities with an SUVmax of 1.0 and thickening of the horizontal duodenum with an SUVmax of 4.0. However, a follow-up gastroscopy did not find any abnormalities in the duodenal tissue.

Why is this case important for doctors?

This case shows that some findings on a scan might look like cancer has spread, but they may just be old issues. Because no biopsy was taken from the duodenum, doctors should not assume a scan finding means lymphoma unless they have a tissue sample to prove it.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BackgroundPulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (pulmonary MALT lymphoma) is an indolent B-cell lymphoma that can mimic infection, inflammatory disease, or epithelial malignancy. Indeterminate fluorodeoxyglucose-avid abnormalities may complicate staging and lead to overinterpretation of disease extent.Case presentationA 49-year-old man with no smoking history underwent video-assisted thoracoscopic right lower-lobe superior segmentectomy for a 12 × 9 mm pulmonary nodule. Histopathology and immunohistochemistry supported pulmonary MALT lymphoma, and fluorescence in situ hybridization detected a BIRC3::MALT1 (formerly API2-MALT1) fusion in 35% of analyzed cells. Resection margins were negative; the only separately documented LN7 lymph node showed reactive hyperplasia without lymphoma, and bone marrow examination was negative. PET/CT performed 11 days after surgery showed expected postoperative inflammatory uptake, mildly avid right upper-lobe ground-glass opacities (SUVmax 1.0), and circumferential thickening of the horizontal duodenum (SUVmax 4.0). Review of serial preoperative CT reports showed that the additional right-lung ground-glass opacities had been present since at least January 2021 and were largely stable through March 2025. Gastroscopy showed no duodenal mucosal abnormality, no biopsy was obtained, and the duodenal finding remained essentially unchanged after rituximab-based systemic therapy. The minimum confirmed extent was therefore a resected pulmonary MALT lymphoma without proven nodal, marrow, additional pulmonary, or gastrointestinal involvement.ConclusionMild FDG uptake in longstanding pulmonary opacities and an unbiopsied gastrointestinal abnormality should not be interpreted as lymphoma dissemination. Histopathology, immunophenotyping, molecular testing, longitudinal imaging, and pathologic confirmation of suspected additional sites should be integrated before disease extent and treatment response are assigned.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.